PROCEPT BioRobotics Corporation

NASDAQ:PRCT

Medical - Devices

Healthcare
$25.18 +0.89%

+$0.19 today

Market cap
$1.45B
Beta
0.85
P/E (TTM)
-11.6
EPS (TTM)
-$1.81
52W Low $19.35High $62.17

Volume 2.05M

Average 1.46M

PRCT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

PROCEPT BioRobotics CorporationNASDAQ: PRCT

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 56.51M shares rose 2.9% year over year, behind the +5.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +7.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.9% toward the trailing-twelve-month pace of +5.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
56.51M+0.8% QoQ
Last fiscal yearDec 2025
55.54M+6.6% YoY
LTMMar 2026
55.94M+5.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.9%——
1 year+6.6%——
3-year CAGR+7.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
55.54M USD
Year-over-year change
+6.6%
4-year CAGR
+6.2%

Weighted Avg Shares vs competitors

How PRCT compares with its peers on the latest reported figures

  • PRCT's LTM Mar 2026 weighted avg shares of 55.94M shares is the 2nd highest of the 5 companies compared; the peer median is 46.09M shares.
  • Its year-over-year change of +5.4% is the 3rd highest of 4, against a peer median of +11.9%.
  • Over three fiscal years its annual growth of +7.8% compares with a peer median of +45.1%.
PRCT Competitors Peer median
Weighted Avg Shares for PRCT and competitors
Company Period LTM YoY 3-year CAGR
SSIISS Innovations International, Inc.LTM Mar 2026193.29M +11.9%+262.7%
PRCTPROCEPT BioRobotics CorporationLTM Mar 202655.94M +5.4%+7.8%
MBOTMicrobot Medical Inc.LTM Mar 202654.72M +234.9%+84.8%
FOCLEDAP TMS S.A. American Depositary SharesLTM Mar 202637.45M —+2.9%
CLPTClearPoint Neuro, Inc.LTM Mar 202628.64M +4.3%+5.4%
Peer median (excluding PRCT) 46.09M+11.9%+45.1%

Competitors are the stored peer set for PRCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.47M75.01M136.19M224.5M308.05M
Cost of Revenue18.61M37.93M65.14M87.4M111.83M
Gross Profit15.87M37.09M71.05M137.1M196.23M
Gross Margin46.0%49.4%52.2%61.1%63.7%
Research & Development18.99M28.98M48.45M62.3M71.28M
Selling, General & Admin51.04M88.83M131.77M171.42M228.81M
Operating Expenses70.03M117.81M180.22M233.71M300.09M
Depreciation & Amortization3.32M2.84M3.81M5.23M6.39M
EBITDA(50.72M)(79.13M)(98.1M)(82M)(85.41M)
EBITDA Margin-147.1%-105.5%-72.0%-36.5%-27.7%
Operating Income(54.16M)(80.72M)(109.17M)(96.61M)(103.86M)
Operating Margin-157.1%-107.6%-80.2%-43.0%-33.7%
Interest Income76K2.5M7.55M10.9M12.22M
Interest Expense5.81M5.18M4M4.18M3.59M
Other Income / Expenses(5.69M)(6.43M)3.27M5.2M8.48M
Income Before Tax(59.85M)(87.15M)(105.9M)(91.41M)(95.38M)
Pre-Tax Margin-173.6%-116.2%-77.8%-40.7%-31.0%
Income Tax Expense0000190K
Net Income(59.85M)(87.15M)(105.9M)(91.41M)(95.57M)
Net Margin-173.6%-116.2%-77.8%-40.7%-31.0%
EPS (Basic)(1.37)(1.96)(2.24)(1.75)(1.72)
EPS (Diluted)(1.37)(1.96)(2.24)(1.75)(1.72)
Weighted Avg Shares43.7M44.4M47.26M52.13M55.54M
Weighted Avg Shares (Diluted)43.7M44.4M47.26M52.13M55.54M

PROCEPT BioRobotics Corporation

NASDAQ:PRCT

Intrinsic Alpha fair value

Locked

Current Price

$25.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.